Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
6th grade Avg
|
|
New words:
abdominal, abnormal, ALZA, anakinra, antibody, apparently, ASTA, AstraZeneca, Atrix, attached, Barry, Baxter, Bayer, Beckman, blackout, Bonanni, book, Bulletin, capable, charitable, children, classified, classify, clerk, concurred, constipation, contention, contributory, convict, Coulter, criteria, curative, cure, daily, darbepoetin, depot, disbursement, dispose, disseminated, distinct, Donald, driven, education, EITF, epratuzumab, equivalent, erythropoietic, estoppel, estrogen, Fabrizio, fall, feasible, Fee, flow, forecast, forecasting, formally, Foundation, fourteen, Glaxo, GlaxoSmithKline, GM, GnRH, gonadotropin, goodwill, ground, gynecologic, HCV, history, HMR, Howard, hyperglycosylated, Idec, immunodeficiency, Immunology, inequitable, infergen, insufficiency, kinase, Kinetix, Kosan, literal, literally, lived, lose, lymphoma, malignant, Medford, Medica, met, mid, monoclonal, Morrow, multiple, multiplied, nephrology, NHL, notification, operon, osteoclast, overdraft, palliative, passed, Paul, pegylated, pelvic, Perlmutter, pituitary, platform, plc, priority, PTH, relapsed, release, releasing, reliance, reopen, revoked, Rice, Rituximab, Roger, SAB, Schehr, science, Sharesave, shrinking, spread, stockpiling, substantive, surface, TAP, Task, testosterone, thousandth, title, trend, untreated, uterine, viable, weekly, Wellcome, write
Removed:
AAA, accelerating, Alton, animal, antitrust, assign, asthma, bankruptcy, Bio, Biosintetica, breach, breached, brought, Canadian, Chapter, Chicago, component, Costa, County, Daryl, de, decided, diabetic, donation, edward, Elanex, endocrinology, exceeded, expose, external, fact, FoxMeyer, full, generic, GmbH, heard, Hill, hospital, implement, improving, investigate, irradiation, joined, Kirby, Latham, launch, ligand, Lunar, marketplace, McKesson, Merckle, migration, NESP, neurobiology, neuropathy, Pacific, permit, planned, platelet, punitive, pursue, remained, removed, Repayment, request, resolved, respiratory, Rica, Rorer, Seattle, selected, stay, succeeding, supportive, surgery, syndrome, target, thereof, TNFbp, Tokyo, twelve, UK, unaffiliated, unfavorable, unpaid, unrelated, Vandeman, warrant
Filing tables
Filing exhibits
- 10-K Annual report
- 3.4 Certificate of Designation of Preferred Stock
- 10.1 Amended and Restated 1991 Equity Incentive Plan
- 10.2 Amended 1997 Non-officer Equity Incentive Plan
- 10.3 Shareholders' Agreement of Kirin-amgen, Inc.
- 10.9 Amendment Nos 4 and 5 to Shareholders' Agreement
- 10.10 Assignment and License Agreement
- 10.11 G-CSF European License Agreement
- 10.12 Company's Retirement and Savings Plan
- 10.14 First Amend to Amgen Retirement and Savings Plan
- 10.22 G-CSF United States License Agreement
- 10.23 Amendment No 1 to G-CSF Us License Agreement
- 10.24 Amendment No 2 to G-CSF Us License Agreement
- 10.25 Amendment No 10 to Shareholders' Agreement
- 10.29 Amendment No 11 to Shareholders' Agreement
- 10.31 Amendment No 1 to G-CSF European License Agreement
- 10.32 Amendment No 2 to G-CSF European License Agreement
- 10.33 Amendment No 3 to G-CSF European License Agreement
- 10.34 Amendment No 4 to G-CSF European License Agreement
- 10.40 Amendment and Restated 1997 Equity Incentive Plan
- 10.42 Amendment No 6 to Shareholders' Agreement
- 10.43 Amendment No 7 to Shareholders' Agreement
- 10.44 Amendment No 8 to Shareholders' Agreement
- 10.45 Amendment No 9 to Shareholders' Agreement
- 21 Subsidiaries of the Company
AMGN similar filings
External links